How GLP-1 Drugs Like Ozempic Are Boostin...

A rare group of dividend-paying stocks are standing out for their exceptional qualities. They’ve racked up five straight years of dividend growth of 10% or more. And they’ve passed several rigorous checks. Morningstar’s DividendInvestor newsletter editor David Harrell dug into th ... Show More

What’s fueling Wall Street’s optimism? While geopolitical tensions between the US and Iran are dominating headlines, US stocks recently hit an all-time high. The global oil shock is just one major disruption to rattle investors before receding this year. The enthusiasm for the ar ... Show More

Vanguard redefined investor-first for the better, and it’s aiming to maintain that reputation. Vanguard revolutionized passive investing when it created the first retail index fund. The behemoth asset manager continues to attract swells of everyday investors and money with headli ... Show More

Shares in Eli Lilly surged on Friday  after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of the fastest growing markets in medicine. Shares of the drug’s originator Chugai ... Show More

<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide. Featuring: Sara Heath, executive editor, Xtelligent Healthcare Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent ... Show More

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More

On this episode of Stock Movers: - Novo Nordisk will slash 9,000 jobs globally and cut its profit forecast for the third time this year as it fights to recover ground lost to its more efficient rival Eli Lilly & Co. in the booming obesity drug market. - Associated British Foods s ... Show More

<p>For decades, Big Food has been marketing products to people who can’t seem to stop eating, and now, suddenly, they can. The active ingredient in new drugs like Ozempic, Wegovy and Zepbound mimics a natural hormone that slows digestion and signals fullness to the brain.</p><p>A ... Show More

<p dir="ltr">Ozempic is a drug used to treat type 2 diabetes and obesity but social media influencers have now turned it into the most popular weight loss drug. Promotion of the drug has led to a shortage of supply with Australia's drugs regulator now investigating the matter. Ho ... Show More

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica ... Show More

<p>Stocks jumping to start the week, as investors hope President Trump may be softening his stance on tariffs. If you can believe the bounce, and the sectors seeing the biggest gains. Plus One pharma company looking to tip the scales in the weight loss drug space. What the CEO of ... Show More

Eli Lilly is the world's most valuable drug company, known for its blockbuster anti-obesity drugs that's transforming America. In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see ... Show More